Federal Supply Schedule 36F79721D0020
Award Date
11/1/20
Last Date to Order
3/20/22
Federal Agency
Veterans Integrated Service Network 12
Awardee
Viela Bio, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Other Statutory Authority
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Viela Bio, Inc. for the delivery of Uplizna. With a potential value of $4,348,680, the BPA has a period of performance through December 28, 2020. Under this agreement, Viela Bio will provide the drug Uplizna to treat neuromyelitis optica spectrum disorder, a rare inflammatory disease of the central nervous system. The Department of Veterans Affairs procures pharmaceuticals...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Viela Bio, Inc. for the pharmaceutical Uplizna. With a potential value of $4,348,680, the single award BPA has a period of performance through May 5, 2022 and was awarded on January 12, 2021. The BPA was established against the Pharmaceuticals and Drugs GSA schedule to provide Uplizna, which is indicated for the treatment of neuromyelitis optica spectrum disorder in adult patients...
The U.S. Department of Veterans Affairs (VA) has awarded multiple Firm Fixed Price delivery orders and Blanket Purchase Agreements (BPAs) to UCB, Inc., a global biopharmaceutical company, under the VA's General Services Administration (GSA) Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The delivery orders, valued between $65,982.84 and $370,099.80, are for the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. UCB, Inc. also holds two...
The Department of Veterans Affairs (VA) awarded a 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals, and hematology-related products to Provention Bio Inc., a biopharmaceutical company. This FSS contract, awarded by the VA's VISN 12 in July 2023, allows the VA to procure Provention Bio's pharmaceutical products, including TZIELD, to support VA healthcare programs serving veterans. Additionally, the VA National Acquisition Center awarded...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The U.S. Department of Veterans Affairs (VA) has awarded a multiple award Federal Supply Schedule (FSS-61-IB) contract to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company, with a ceiling value of $78 million through July 2025. This contract enables the VA to procure pharmaceuticals and drug products, such as TEGSEDI and ORFADIN, to support healthcare services for veterans. Additionally, the VA National Acquisition Center has awarded a single-award Blanket Purchase Agreement (BPA)...
The U.S. Department of Veterans Affairs (VA) awarded a $225,000 multiple award Federal Supply Schedule contract to Albireo Pharma, Inc., a for-profit manufacturer of pharmaceuticals and drugs, under the Pharmaceuticals and Drugs schedule. The contract has a period of performance from March 2022 to March 2027, allowing the VA Veterans Integrated Service Network 12 to order various pharmaceuticals. Additionally, the VA National Acquisition Center awarded a $883,061.15 single-award Blanket Purchase...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 awarded a Federal Supply Schedule (FSS) contract to Urovant Sciences Inc., a subsidiary of Sumitovant Biopharma, Inc. This multiple-award contract is for the procurement of drugs, pharmaceuticals, and hematology-related products under FSS-61-IB. The contract has a potential value of $700,000.00 and a period of performance through September 14, 2026. The contract aims to provide the Department...
The Federal Supply Schedule (FSS) contract and Blanket Purchase Agreement (BPA) awarded to Bluebird Bio, Inc. by the U.S. Department of Veterans Affairs (VA) demonstrate the agency's interest in leveraging the company's gene therapies and hematology products to address the medical needs of the veteran population. The first IDV is a multiple-award, Schedule 65 IB FSS contract with a potential value of $300,000, which allows the VA's Veterans Integrated Service Network 12 to procure drugs,...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans. In addition to the FSS...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
36F79721D0020-36E79721A0007 | Viela Bio, Inc. | $4.3m | 1/12/21 | 5/5/22 | 5/5/22 |